NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary NanoPortal technology associated with this agreement.

Separately, Vivani expects to initiate a Phase 1, randomized, first-in-human study evaluating the NPM-139 semaglutide implant, with Wegovy® injections as an active comparator, in mid-2026. The study’s objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM-139 to support the initiation of a Phase 2 dose-ranging study pending successful results of the Phase 1 study.

Adam Mendelsohn, Ph.D., Vivani President and CEO, stated: "The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary."